FDA dings Celgene over Otezla TV ad

|About: Celgene Corporation (CELG)|By:, SA News Editor

The Fly reports that the FDA has sent a letter to Celgene (CELG +0.9%) stating that its direct-to-consumer television advertisement for psoriasis med Otezla (apremilast) makes "false or misleading" representations about the drug's risks. The FDA added, "this violation is concerning from a public health perspective because it creates a misleading impression about the safety of Otezla."

Subscribe for full text news in your inbox